With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
BioPharma Dive
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a mandate on rare disease flexibility.
pharminent
May 14, 2026 (Last updated: May 14, 2026)
BioPharma Dive
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a mandate on rare disease flexibility.
